authors: _[Andrew T Levin](https://sites.dartmouth.edu/alevin), Nana Owusu-Boaitey, Sierra Pugh, [Bailey K Fosdick](https://www.baileyfosdick.com/), [Anthony B. Zwi](https://research.unsw.edu.au/people/professor-anthony-zwi), [Anup Malani](https://www.law.uchicago.edu/faculty/malani), [Satej Soman](https://www.ischool.berkeley.edu/people/satej-soman), [Lonni Besan√ßon](http://lonnibesancon.me/), [Ilya Kashnitsky](https://www.sdu.dk/en/forskning/forskningsenheder/samf/cpop/about_the_centre/our_people/cpop_dem/ilya_kashnitsky), Sachin Ganesh, Aloysius McLaughlin, Gayeong Song, Rine Uhm, [Gideon Meyerowitz-Katz](https://gidmk.medium.com/about)_

# Links 
- [MedRxiv preprint](https://www.medrxiv.org/content/10.1101/2021.09.29.21264325v1) of our paper
- [Medium blog](https://elemental.medium.com/the-death-rate-of-covid-19-in-developing-countries-cc17a55c73cd) about our findings
- Data and code:
  - [input data](https://github.com/covid-ifr/assessing-burden/tree/main/input_data)
  - [statistical model](https://github.com/covid-ifr/assessing-burden/blob/main/model/ifrEstimation.stan)
  - [model output](https://github.com/covid-ifr/assessing-burden/tree/main/model_output)

# Highlights
- Age-specific prevalence and infection fatality rate (IFR) of COVID-19 for developing countries has not been well assessed.
- Seroprevalence in developing countries (as measured by antibodies against SARS-CoV-2) is markedly higher than in high-income countries but still far short of herd immunity.
- Seroprevalence among older adults is broadly similar to that of younger age-groups.
- Age-specific IFRs in developing countries are roughly twice those of high-income countries.
- Population IFR in developing countries with satisfactory death reporting (based on UN/WHO data as of 2016) is ten times higher than in other developing countries.
- These results underscore the urgency of disseminating vaccines to vulnerable people in developing countries.

# Figures

### Study Locations
<span> ![](https://raw.githubusercontent.com/covid-ifr/covid-ifr.github.io/main/assets/img/assessingburden-2a.png) ![](https://raw.githubusercontent.com/covid-ifr/covid-ifr.github.io/main/assets/img/assessingburden-2b.png)  </span>
### Seroprevalence Map
![](https://raw.githubusercontent.com/covid-ifr/covid-ifr.github.io/main/assets/img/assessingburden-3.png)
### Age-Specific Seroprevalence 
![](https://raw.githubusercontent.com/covid-ifr/covid-ifr.github.io/main/assets/img/assessingburden-5.png)
### Seroprevalence Ratios
![](https://raw.githubusercontent.com/covid-ifr/covid-ifr.github.io/main/assets/img/assessingburden-6.png)
### Population IFR (ages 18-65)
![](https://raw.githubusercontent.com/covid-ifr/covid-ifr.github.io/main/assets/img/assessingburden-7.png)
### Metaregression Results
![](https://raw.githubusercontent.com/covid-ifr/covid-ifr.github.io/main/assets/img/assessingburden-8.png)
### National IFRs
![](https://raw.githubusercontent.com/covid-ifr/covid-ifr.github.io/main/assets/img/assessingburden-9.png)
### Population IFRs by Location
![](https://raw.githubusercontent.com/covid-ifr/covid-ifr.github.io/main/assets/img/assessingburden-10.png)

